Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative ...

(SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe stress-related conditions ... severe ...

This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown ...

Cybin has reported 71% remission in patients with major depressive disorder (MDD) who received two doses of the ... that are ...

One major approach is to learn what ... The role of exposure in treatment of anxiety disorders: A meta-analysis.

On a sunny day in July, while other Bay Area kids were playing at camps or water parks, 8-year-old Charlotte O’Neill was leaning back in a reclining chair in a small, carpeted San Jose office room.

Greenbrook TMS Inc. ("Greenbrook" or the "Company") is pleased to announce that the Company has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the ...

Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...